Source:http://linkedlifedata.com/resource/pubmed/id/21435845
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
2
|
| pubmed:dateCreated |
2011-4-25
|
| pubmed:abstractText |
The aim of this study was to design docetaxel-loaded nanostructured lipid carriers (DTX-NLC) to reduce toxicity and improve therapeutic efficacy. Docetaxel-loaded nanostructured lipid carriers (DTX-NLC) were prepared by the modified film ultrasonication-dispersion method. The DTX-NLC were characterized by particle size distribution, zeta potential and entrapment efficiency. In vitro cytotoxicity of DTX-NLC was evaluated by MTT assay against three human cancer cell lines and one murine malignant melanoma (B16). AnnexinV-FITC kit was used to measure the percentage of apoptosis induced by Duopafei(®) or DTX-NLC. In vivo anti-tumor efficacy was evaluated in Kunming mice bearing murine malignant melanoma (B16). Compared with Duopafei(®), DTX-NLC revealed more cytotoxicity against A549 cells by inducing more apoptosis and more G2/M arrest. The inhibition rates of Duopafei(®), DTX-NLC (10mg/kg) and DTX-NLC (20 mg/kg) were 42.74%, 62.69% and 90.36%, respectively, indicating that DTX-NLC could more effectively inhibit tumor growth. The results of the body weight variations of mice also showed that compared with Duopafei(®), DTX-NLC had lower toxicity during the therapeutic procedure. These results suggest that DTX-NLC may be a promising drug delivery system for cancer therapy. To our knowledge, this was the first report about DTX-NLC for murine malignant melanoma treatment.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Drug Carriers,
http://linkedlifedata.com/resource/pubmed/chemical/Lipids,
http://linkedlifedata.com/resource/pubmed/chemical/Taxoids,
http://linkedlifedata.com/resource/pubmed/chemical/docetaxel
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jul
|
| pubmed:issn |
1873-4367
|
| pubmed:author | |
| pubmed:copyrightInfo |
Copyright © 2011 Elsevier B.V. All rights reserved.
|
| pubmed:issnType |
Electronic
|
| pubmed:day |
1
|
| pubmed:volume |
85
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
262-9
|
| pubmed:meshHeading |
pubmed-meshheading:21435845-Animals,
pubmed-meshheading:21435845-Antineoplastic Agents,
pubmed-meshheading:21435845-Apoptosis,
pubmed-meshheading:21435845-Cell Cycle,
pubmed-meshheading:21435845-Cell Line,
pubmed-meshheading:21435845-Cell Line, Tumor,
pubmed-meshheading:21435845-Cell Proliferation,
pubmed-meshheading:21435845-Cell Survival,
pubmed-meshheading:21435845-Dose-Response Relationship, Drug,
pubmed-meshheading:21435845-Drug Carriers,
pubmed-meshheading:21435845-Drug Delivery Systems,
pubmed-meshheading:21435845-Flow Cytometry,
pubmed-meshheading:21435845-Hep G2 Cells,
pubmed-meshheading:21435845-Humans,
pubmed-meshheading:21435845-Kinetics,
pubmed-meshheading:21435845-Lipids,
pubmed-meshheading:21435845-Melanoma, Experimental,
pubmed-meshheading:21435845-Mice,
pubmed-meshheading:21435845-Microscopy, Electron, Transmission,
pubmed-meshheading:21435845-Nanostructures,
pubmed-meshheading:21435845-Taxoids,
pubmed-meshheading:21435845-Treatment Outcome
|
| pubmed:year |
2011
|
| pubmed:articleTitle |
Nanostructured lipid carriers as novel carrier for parenteral delivery of docetaxel.
|
| pubmed:affiliation |
School of Pharmaceutical Science, Shandong University, 44 Wenhua Xi Road, Ji'nan 250012, China.
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|